PharmiWeb.com - Global Pharma News & Resources
21-Nov-2018

Global Hydronephrosis Therapies Market Report 2019-2023 - ResearchAndMarkets.com

The "Global Hydronephrosis Therapies Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The Global Hydronephrosis Therapies Market to grow at a CAGR of 9.14% during the period 2019-2023.

The report covers the present scenario and the growth prospects of the hydronephrosis therapies market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of hydronephrosis across the globe.The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend affecting this market is the increasing awareness of kidney diseases. Kidney diseases are the major causes of hydronephrosis. However, early-stage kidney disease is typically asymptomatic and may not notice any symptoms, which, in turn, leads to low levels of awareness in people with CKD.

According to the report, one driver influencing this market is the driven by growing prevalence of kidney diseases that result in a higher incidence of hydronephrosis. Hydronephrosis is caused by kidney related diseases such as UTIs, CKDs, and kidney stones. According to the CDC, around 30 million people in the US are affected by CKD, which is likely to augment the growth of the global hydronephrosis treatment market. Furthermore, the increasing prevalence of ESRD, another kidney related disorder, will drive the demand for treatment of hydronephrosis across the period of forecast.

Further, the report states that one challenge affecting this market is the availability of alternate therapies. The growth of the market is impeded by the fact that despite having medications for the treatment of the underlying cause of hydronephrosis, there are several alternative procedures for the management of hydronephrosis.

Key questions answered in this report

  • What will the market size be in 2023 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the Key vendors in this market space?
  • What are the market opportunities and threats faced by the Key vendors?
  • What are the strengths and weaknesses of the Key vendors?

Market Dynamics

  • Growing prevalence of kidney diseases that result in a higher incidence of hydronephrosis
  • Availability of alternate therapies
  • Increasing awareness of kidney diseases

Key vendors

  • Allergan
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Antibiotic therapy - Market size and forecast 2018-2023
  • Other therapies - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Allergan
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

PART 14: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/4c83b2/global?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181121005266/en/

Editor Details

Last Updated: 21-Nov-2018